Ülke: Ermenistan
Dil: İngilizce
Kaynak: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
paracetamol, phenylephrine (phenylephrine hydrochloride), ascorbic acid
SmithKline Beecham S.A. Ctra. de Ajalvir
N02BE51
paracetamol, phenylephrine (phenylephrine hydrochloride), ascorbic acid
750mg+ 10mg+ 60mg
powder for oral solution with honey and lemon flavour
(10) sachets 5g
OTC
Registered
2017-06-27
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Coldrex® HotRem 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE CONSTITUENTS: Paracetamol 750.00 mg Phenylephrine Hydrochloride 10.00 mg Ascorbic acid 60.00 mg 3. PHARMACEUTICAL FORM Powder for Oral Solution with honey and lemon flavour Sachet content: heterogeneous powder from off-white with beige shade to bright – brown, with white, bright-brown and dark-brown inclusions. Solution in hot water: opaque, from bright-yellow to bright-brown, with non-dissolving white inclusions and characteristic honey and lemon flavour. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS The short term symptomatic relief of cold & flu symptoms including fever, headache, body aches and pains, nasal congestion, sore throat, sinusitis and its associated pain. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral administration only. Empty the contents of the sachet into a glass, fill with hot water, stir until dissolved. Add cold water as necessary. Adults (including the elderly) and children aged 12 years and over: One sachet to be taken every four to six hours as required. Maximum daily dose 5 sachets in any 24 hour period. Minimum dosing interval: 4 hours. Not recommended for children under the age of 12 years, except on medical advice. Maximum duration of use without medical advice: 7 days. If symptoms persist, consult a doctor. Do not exceed the stated dose. The lowest effective dose and shortest duration of treatment should be considered. 4.3 CONTRAINDICATIONS This product is contraindicated in patients with: • Hypersensitivity to paracetamol, phenylephrine, ascorbic acid or any of the excipients; • Who are taking, or have taken, within the last two weeks, monoamine oxidase inhibitors, which typically are used to treat depression; • Pheochromocytoma; • Closed-angle glaucoma; • Hepatic or severe renal insufficiency; • Hypertension; • Hyperthyroidism; • Diabetes • Heart disease • Taking beta-blockers and tricyclic antidepressants. Do not ta Belgenin tamamını okuyun